Observation of Safety and Efficacy of Botulinum Toxin Type A in the Treatment of Tear Troughs and Mild Yelid Bags

OBJECTIVE: To evaluate the safety and efficacy of Botulinum Toxin Type A (BTX-A) injection for the treatment of tear troughs. METHOD: This study included patients with tear troughs rated as Grade 1-2 on the Barton Aesthetic Scale, who were treated between September 2023 and September 2024. These patients underwent intradermal injections of Botulinum Toxin Type A (BTX-A). Doctors conducted pre- and post-procedure assessments of the severity of tear troughs using the Barton Scale and TTRS (The Tear Trough Rating Scale). VISIA skin image analyzer (Canfield, USA) was utilized to compare the number of wrinkles, and facial scores and percentiles were calculated for objective evaluations before and after treatment. Additionally, doctors employed the Fitzpatrick Scale to assess periorbital wrinkles. This investigation was conducted as a prospective single-center study (PSS). RESULTS: All 42 patients completed the study. After treatment, there was a significant improvement in VISIA-measured wrinkle count, facial scores, and percentiles. Additionally, there were significant reductions in Barton, TTRS, and Fitzpatrick scores. One case of pseudo-eyelid bags was observed post-treatment, while no other complications such as diplopia, lower eyelid skin laxity, or other adverse effects were reported. CONCLUSION: BTX-A is effective in improving mild tear troughs while simultaneously reducing fine lines in the lower eyelid. Patients were highly satisfied with the improved appearance.